Detailed answers about PRINCETON BIOPARTNERS (UK SUBSIDIARY) LIMITED, including incorporation, status, business activity, and accounts information.
When was PRINCETON BIOPARTNERS (UK SUBSIDIARY) LIMITED founded?
PRINCETON BIOPARTNERS (UK SUBSIDIARY) LIMITED was officially incorporated on 28 March 2025 and is registered under company number 16350762. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
What type of company is PRINCETON BIOPARTNERS (UK SUBSIDIARY) LIMITED?
Private Limited Company. This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations. A private limited company (Ltd) limits the personal liability of its shareholders.
What is the current status of PRINCETON BIOPARTNERS (UK SUBSIDIARY) LIMITED?
PRINCETON BIOPARTNERS (UK SUBSIDIARY) LIMITED's current status is Active. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
What does PRINCETON BIOPARTNERS (UK SUBSIDIARY) LIMITED do?
PRINCETON BIOPARTNERS (UK SUBSIDIARY) LIMITED operates in the following sector: 74909 - Other professional, scientific and technical activities n.e.c.. This provides insight into the company's primary business activity and industry focus.
What is PRINCETON BIOPARTNERS (UK SUBSIDIARY) LIMITED's registered address?
The registered office address of PRINCETON BIOPARTNERS (UK SUBSIDIARY) LIMITED is 3RD FLOOR THE COADE, 98 VAUXHALL WALK, LONDON, UNITED KINGDOM, SE11 5EL. This is the official address filed with Companies House for legal and statutory correspondence.
Is PRINCETON BIOPARTNERS (UK SUBSIDIARY) LIMITED financially stable?
Financial accounts for PRINCETON BIOPARTNERS (UK SUBSIDIARY) LIMITED are not currently available. Without filed accounts, it is more difficult to assess the company's financial stability and trading performance.